Tagged with Opinion

Opinion Jonathan Kimball of the Association for Accessible Medicines (AAM) in the USA outlines why the signing of the US-Mexico-Canada Agreement (USMCA) in January 2020 may mark a turning point for greater access to generic and biosimilar medicines globally.   US trading partners should take note. There is no longer a…

Opinion Brendan Shaw outlines the long road still to travel to meet the UN Sustainable Development goal of ensuring basic healthcare financing for every citizen in the world by 2030 and the vital role that the private sector must play in attempting to meet this challenge.   The majority of developing…

China Eurasia Group’s Aditya Bhattacharji examines the unfolding coronavirus outbreak, the prospects for China’s political and economic stability, and how healthcare firms should think about the path forward. China appears to be ground zero for a public health experiment with no recent analogues. The situation—in terms of social and economic dislocation—deteriorates…

USA Takeda’s Jessica S. Scott examines the steps already being taken to bring greater patient engagement to drug development and the regulatory decision-making process in the USA; as well as what more needs to be done in this crucial area.   Steps Taken by FDA Under the Food and Drug Administration…

USA The Association for Accessible Medicines’ Chip Davis outlines the ways in which the US Medicare programme needs updating in order to promote generic and biosimilar competition and therefore increase patient access to more affordable medicines.   In this election year I hope that the candidates will lay out their solutions…

Opinion Health Catalyst’s Elia Stupka explains why and how patients must be kept at the centre of the healthcare systems of the future, even as they become increasingly data-driven.   Healthcare data is seen by many as the ‘new goldmine,’ with many businesses in this field evaluated and sold at a significant…

USA David Crean summarises the mood at the recent J.P. Morgan Healthcare Conference 2020 in San Francisco, noting a more subdued atmosphere than previous years, with reduced attendances and no big M&A announcements. Crean does, however, underline the importance of the Conference for industry networking and highlights some of the biopharma…

Canada John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the forefront of the next wave of global biopharmaceutical R&D. BlueRock Therapeutics, a promising North American start-up with a new Parkinson’s disease drug, was recently sold to Germany’s Bayer at a $1 billion valuation.…

Europe Isabell Remus, chair of the Biosimilar Medicines Group at Medicines for Europe outlines the issues that need to be addressed to keep driving biosimilar uptake in Europe.   Since the first treatment was approved in 2006, Europe has been at the vanguard of the biosimilar medicines sector, approving more treatments…

Opinion BIO’s Greg Frank outlines the alarming growth of drug-resistant infections and the steps that need to be taken to combat this rapidly emerging global health threat.   Drug-resistant superbugs are evolving at a rapid pace. In fact, it is estimated that 700,000 people die from drug-resistant infections each year. Without…

USA Eurasia Group’s Aditya Bhattacharji examines the stalling of healthcare reforms in the US and what changes to US healthcare it is realistic to expect.   Pharma is unlikely to be frog-marched by sweeping federal initiatives, but more incremental changes are likely With anti-pharma sentiment raging at the end of 2018,…

Opinion Nigel Hughes of the European Health Data & Evidence Network (EHDEN) outlines EHDEN’s scope and purpose and highlights why greater collaboration on real-world data (RWD) will be crucial to ensuring better global health outcomes.    Ultimately, EHDEN is striving to ensure 21st century research can be conducted with 21st century…